These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 27510252

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G, Kumar AK, Bhavani PK, Kannan T, Kumar SR, Gangadevi NP, Banurekha VV, Sekar L, Ravichandran N, Mathevan G, Sanjeeva GN, Dayal R, Swaminathan S.
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [Abstract] [Full Text] [Related]

  • 3. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK, Chandrasekaran V, Kannan T, Murali AL, Lavanya J, Sudha V, Swaminathan S, Ramachandran G.
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Swaminathan S.
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
    Ramachandran G, Agibothu Kupparam HK, Vedhachalam C, Thiruvengadam K, Rajagandhi V, Dusthackeer A, Karunaianantham R, Jayapal L, Swaminathan S.
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242663
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [Abstract] [Full Text] [Related]

  • 11. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
    Jutte PC, Rutgers SR, Van Altena R, Uges DR, Van Horn JR.
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1368-72. PubMed ID: 15581207
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP, Medellín-Garibay SE, Salazar-González RA, Ortiz-Álvarez A, Magaña-Aquino M, Rodríguez-Pinal CJ, Portales-Pérez DP, Romano-Moreno S, Milán-Segovia RDC.
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [Abstract] [Full Text] [Related]

  • 14. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, Shahsavari N, Emami S, Habibi M, Salamzadeh J.
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
    Dayal R, Singh Y, Agarwal D, Kumar M, Swaminathan S, Ramachandran G, Kumar S, Narayan S, Goyal A, Kumar AKH.
    Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
    Grosset J, Truffot-Pernot C, Lacroix C, Ji B.
    Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
    [Abstract] [Full Text] [Related]

  • 18. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Di Perri G, Calcagno A.
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM, López D, Hermans PW, Warris A, de Groot R, García JF, de Waard JH, Aarnoutse RE.
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [Abstract] [Full Text] [Related]

  • 20. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
    Ranjalkar J, Mathew SK, Verghese VP, Bose A, Rose W, Gupta D, Fleming DH, Mathew BS.
    Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.